Showing results (1-10 of 279) with videos related to
Sort By:
Pageof 28
Annals of Translational Medicine|August 27, 2016
Melanoma immunotherapy dominates the fieldPanagiotis Diamantopoulos, Helen GogasMedicine|March 10, 2020
A case report of immune-mediated arthritis in a patient with cutaneous melanoma receiving checkpoint inhibition therapyGeorge Papaxoinis, Amalia Anastasopoulou, Katerina Laskari, et al.Immunotherapy|July 19, 2022
Clinical course of COVID-19 infection in a melanoma patient treated with nivolumab and bempegaldesleukin: a case reportAmalia Anastasopoulou, Aikaterini Gkoufa, Panagiotis Diamantopoulos, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 9, 2018
Bullous Pemphigoid-like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the LiteratureAmalia Anastasopoulou, Georgios Papaxoinis, Panagiotis Diamantopoulos, et al.Journal of Chemotherapy (Florence, Italy)|September 14, 2019
A life-threatening drug-drug interaction between capecitabine and brivudine in a patient with metastatic breast cancerAngeliki Tsifi, George Papaxoinis, Panagiotis Diamantopoulos, et al.Diagnostics (Basel, Switzerland)|March 25, 2022
Multichamber Involvement of Metastatic Cardiac MelanomaMaria S Bonou, Panagiotis Diamantopoulos, Sofia Mavrogeni, et al.Journal for Immunotherapy of Cancer|October 17, 2020
Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapyDimitrios C Ziogas, Frosso Kostantinou, Evangelos Cholongitas, et al.Journal for Immunotherapy of Cancer|November 4, 2020
When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case reportDimitrios C Ziogas, Aikaterini Gkoufa, Evangelos Cholongitas, et al.The American Journal of the Medical Sciences|December 21, 2022
Melanuria in a patient with BRAF-mutant metastatic melanoma of unknown primary: Insights on the pathophysiology, differential diagnosis, prognosis, and treatmentPanagiotis Diamantopoulos, Georgios Patavoukas, Andriana Garantzioti, et al.Frontiers in Oncology|October 22, 2024
Immunotherapy after progression to double immunotherapy: pembrolizumab and lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibitionGeorgios Lyrarakis, Michael Liontos, Amalia Anastasopoulou, et al.Pageof 28